MENU

October 03, 2019 (Pantoprazole IV)

September 2, 2019 (Diclofenac and Dexmedetomidine)

September 2, 2019 (Diclofenac and Dexmedetomidine)

April 1 & 15, 2019 (Rabeprazole, etc.)

June 15, 2019 (Norethistherone, etc.)

November 23, 2018 (Reteplase)

October 3, 2018 (Cinacalcet)

October 03, 2019 (Pantoprazole tablet)

September 02, 2019 (Immunoglobulin Normal, Human (IVIG)

May 27, 2019 (Anastrozole, etc.)

December 17, 2018 (Rifapentine)

December 5, 2018 (Levetiracetam, Memantine)

November 2018 (0.9% Sodium Chloride, Tolvaptan)

2020

Medicine/s Name Dosage/s and Strength/s Remarks Issuance
Pantoprazole

•20 mg and 40 mg tablet/enteric-coated tablet

 

- Indication: (1) Treatment of mild, moderate and severe reflux esophagitis, duodenal ulcer, gastric ulcer, Zollinger-Ellison-Syndrome, in combination with two appropriate antibiotics (for the eradication of H. pylori in patients with peptic ulcers with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism) in adults; (2) reflux esophagitis, symptomatic gastroesophageal reflux disease (GERD) in children 5- 17 years of age; (3) prevention of gastroduodenal ulcers induced by continuous nonsteroidal antiinflammatory drug (NSAID)
treatment; and (4) long-term management and prevention of "relapse in reflux esophagitis.

- Government list price:

PHP 27 per 20 mg tablet

PHP 14.50 per 40 mg tablet

Department Memorandum no. 2020-0018